Piramal Pharma has awarded its integrated media mandate to OMD India, part of Omnicom Media Group. Following a multi-round pitch, the agency has been selected to handle the mandate of scaling the brand through sharp, creative and forward-leaning communication efforts.
OMD India will spearhead the strategic marketing and media efforts for Piramal Pharma’s portfolio of OTC brands, including Lacto Calamine, Little’s, Tetmosol, Polycrol, and Women’s intimate health range like i-pill and i-activ, and will be managed out of the agency’s Mumbai office.
Known for its media and digital innovation prowess, OMD will be responsible for deploying an efficient game plan to enhance Piramal Pharma’s presence across markets, boost brand salience, drive consumer engagement, and enable impact-driven marketing strategy to be a driver for business growth.
“We are excited to embark on this partnership with Piramal Consumer Healthcare, a company that mirrors our commitment to innovation and excellence,” said Anisha Iyer, CEO of OMD India. “This collaboration presents a significant opportunity to leverage our strategic acumen and deep market intelligence to elevate Piramal’s impressive portfolio of brands to new heights. Together, we aim to craft media strategies that go beyond visibility—building lasting trust and loyalty with consumers across India and shaping a future of sustained growth and impact.”
This win continues to underscore OMD India’s momentum in the market on the back of strong wins. It was also recently crowned South Asia Agency of the Year and bought home honours as the India Media Agency of the Year (Gold) and Digital Innovation Agency of the Year (Silver) at the Campaign Asia 2024 Agency of the Year awards in December.
